We do not publish a universal dose, because the right protocol depends on your testing, symptoms, and history, and dosing guidance belongs in your individual visit, not a web page
Providers remain available for follow-ups and dose adjustments, helping you stay on track safely and effectively
Theres no way to tell whether a non-response is the product, the dose, or individual variability, and no clinician to call when something goes wrong
Tirzepatide increases heart rate modestly (average 24 bpm in clinical trials), while growth hormone effects on cardiac function require monitoring in susceptible individuals
Safety Considerations There are currently no published studies specifically examining the combination of CJC-1295 and Retatrutide in humans
In receptor binding studies, it has been shown to have a GLP-1R and GLP-1 binding affinity, respectively, about five times lower than that of native and similar to endogenous GIP (40)